Pharmaceutical Industry and Corporate Executive Team
Glaxosmithkline | Unethical Profits | GlaxoSmithKline | | David Messer | 4/29/2013 |
|
David Messer
Jeremy Black
Business 220
April 29, 2013
GlaxoSmithKline
GlaxoSmithKline is a U.K.-based pharmaceutical powerhouse formed by a merger in the late 90’s, with the most important merger being that between Glaxo Wellcome and Smith Kline Beecham. The merger created a pharmaceutical industry giant with operations in over 100 countries and annual sales over $25 billion. In the U.S. alone, prescription drugs account for 10% of all medical costs with sales tripling over the past decade and price increases of 150 percent.
Andrew Witty became Chief Executive Officer of GlaxoSmithKline on 21 May 2008. He is a member of the Board and Corporate Executive Team. Andrew joined Glaxo in 1985 and has held a variety of Sales and Marketing roles in the UK and abroad including working in the Company’s International New Products groups, both in the Respiratory and HIV/Infectious disease fields. Outside of the UK Andrew has worked in South Africa, The USA and Singapore where he led the Group’s operations as Senior Vice President, Asia Pacific. While in Singapore Andrew was a Board Member of the Singapore Economic Development Board and the Singapore Land Authority. In 2003 he was awarded the Public Service Medal by the Government of Singapore and in August 2012 was also awarded the Public Service Star. In 2003 Andrew was appointed President of GSK Europe, and joined GSK’s Corporate Executive Team. Andrew has served in numerous advisory roles to Governments around the world including South Africa, Singapore, Guangzhou China and the UK, where he is currently a member of the Prime Minister’s Business Advisory Group and is the Lead Non-Executive Director for the Department for Business Innovation and Skills. He was awarded a knighthood for services to the economy and to the UK pharmaceutical industry in the 2012 New Year Honors List. In January 2013 Andrew took up
|
David Messer
Jeremy Black
Business 220
April 29, 2013
GlaxoSmithKline
GlaxoSmithKline is a U.K.-based pharmaceutical powerhouse formed by a merger in the late 90’s, with the most important merger being that between Glaxo Wellcome and Smith Kline Beecham. The merger created a pharmaceutical industry giant with operations in over 100 countries and annual sales over $25 billion. In the U.S. alone, prescription drugs account for 10% of all medical costs with sales tripling over the past decade and price increases of 150 percent.
Andrew Witty became Chief Executive Officer of GlaxoSmithKline on 21 May 2008. He is a member of the Board and Corporate Executive Team. Andrew joined Glaxo in 1985 and has held a variety of Sales and Marketing roles in the UK and abroad including working in the Company’s International New Products groups, both in the Respiratory and HIV/Infectious disease fields. Outside of the UK Andrew has worked in South Africa, The USA and Singapore where he led the Group’s operations as Senior Vice President, Asia Pacific. While in Singapore Andrew was a Board Member of the Singapore Economic Development Board and the Singapore Land Authority. In 2003 he was awarded the Public Service Medal by the Government of Singapore and in August 2012 was also awarded the Public Service Star. In 2003 Andrew was appointed President of GSK Europe, and joined GSK’s Corporate Executive Team. Andrew has served in numerous advisory roles to Governments around the world including South Africa, Singapore, Guangzhou China and the UK, where he is currently a member of the Prime Minister’s Business Advisory Group and is the Lead Non-Executive Director for the Department for Business Innovation and Skills. He was awarded a knighthood for services to the economy and to the UK pharmaceutical industry in the 2012 New Year Honors List. In January 2013 Andrew took up
Cited: Ferrell, O.C., John Fraddrich, and Linda Ferrell. Business Ethics. Mason, Ohio. Erin Joyner (publisher). 2011, 2013 Greider, Katharine The Big Fix. PublicAffairs, 2003 Law, Jacky Big Pharma: Exposing the Global Healthcare Agenda. New York. Carrol & Graf Publishers Harris, Gardiner. “Pfizer Pays $2.3 Billion to Settle Marketing Case” NY Times. September 2, 20009.